Luprotas 22.5mg Injection 1's
Key Information
Generic Name
Generic Name Leuprolide 22.5 mg Also Known As: Leuprorelin
Manufacturer
Intas Pharmaceuticals Ltd
Country of Origin
India
Detailed Information
Introduction
INTRODUCTION ABOUT LUPROTAS 22.5MG INJECTIONLUPROTAS 22.5MG INJECTION contains Leuprolide which belongs to the group of medicines called Gonadotropin Releasing Hormone (GnRH) Agonist. It is used for palliative management (relieving symptoms and minimising the associated suffering) of advanced prostatic cancer. Advanced prostatic cancer is a cancer (abnormal cell multiplication and differentiation) that originates in the prostate gland and spreads to the other parts of the body. It is characterized by the symptoms such as painful urination, decreased urine pressure, blood in the semen, bone pain, leg swelling, and weakness. Do not receive LUPROTAS 22.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs. Before receiving the medicine, inform your doctor if you have liver impairment, kidney impairment, congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, metastatic vertebral lesions, urinary tract obstruction, or diabetes. Before receiving this medicine, inform your doctor if you have a history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies/tumours. LUPROTAS 22.5MG INJECTION is not recommended for use in pregnant women, breastfeeding women, and children. It should be used with caution in elderly patients (aged above 65 years). Consult your doctor before receiving. The most common
Uses
OF LUPROTAS 22.5MG INJECTION Used for palliative management (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer
How It Works
LUPROTAS 22.5MG INJECTION contains Leuprolide which works by blocking the secretion of gonadotropin releasing hormone (GnRH) following an initial stimulation, resulting in suppression of ovarian and testicular steroidogenesis (process of synthesis of steroid hormones), thereby relieving the symptoms associated with increased testosterone levels in advanced prostatic cancer.
Directions for Use
LUPROTAS 22.5MG INJECTION will be administered to you only by a doctor or a nurse intramuscularly (into the muscle) or subcutaneously (under the skin). Your doctor will administer the correct dose and duration for you depending upon your age, body weight and disease condition.
Side Effects
LUPROTAS 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in upper respiratory tract, and fatigue. Consult your doctor if any of these side effects worsens. USES OF LUPROTAS 22.5MG INJECTION Used for palliative management (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer HOW LUPROTAS 22.5MG INJECTION WORKSLUPROTAS 22.5MG INJECTION contains Leuprolide which works by blocking the secretion of gonadotropin releasing hormone (GnRH) following an initial stimulation, resulting in suppression of ovarian and testicular steroidogenesis (process of synthesis of steroid hormones), thereby relieving the symptoms associated with increased testosterone levels in advanced prostatic cancer. DIRECTIONS FOR USELUPROTAS 22.5MG INJECTION will be administered to you only by a doctor or a nurse intramuscularly (into the muscle) or subcutaneously (under the skin). Your doctor will administer the correct dose and duration for you depending upon your age, body weight and disease condition. SIDE EFFECTS OF LUPROTAS 22.5MG INJECTIONCOMMON hot flashes, sweating general pain in the body pain at the site of injection gastrointestinal disorders respiratory disorders urinary disorders shrinking of testicles extreme weakness headache joint disorders dizziness neuromuscular disorders skin reactions flu-syndrome dehydration muscle pain sensation of pins and needles lethargy constipation sinus headache influenza-like illness including influenza, nasopharyngitis, nasal congestion, upper respiratory tract infection, rhinorrhea, and viral upper respiratory tract infection cough hemorrhagic cystitis high blood pressure rash urinary tract infection cystitis (an inflammatory condition of bladder) decreased haemoglobin increased frequency of urination in night peripheral/pitting oedema (swelling in legs and feet due to water retention) itching hair loss pain in testicles clamminess breast enlargement in males reduced libido Stop receiving LUPROTAS 22.5MG INJECTION and contact your doctor if you experience any of the following side effects: COPD (chronic obstructive pulmonary disease) coronary artery disease (heart disease) is characterized by angina (chest pain) cerebrovascular accident/transient ischemic attack (life-threatening events related to impaired heart function) pneumonia (a life-threatening lung disease) second primary neoplasm (cancer) including basal cell carcinoma, lung neoplasm, bladder transitional cell carcinoma, malignant melanoma, squamous cell carcinoma, non-Hodgkin’s lymphoma
Warnings & Precautions
& PRECAUTIONSPREGNANCYContraindicatedLUPROTAS 22.5MG INJECTION is not recommended for use during pregnancy. Consult your doctor before receiving the medicine. BREASTFEEDINGContraindicatedLUPROTAS 22.5MG INJECTION is not recommended for use in breastfeeding women as it can pass through milk. Consult your doctor before receiving the medicine. DRIVING AND USING MACHINESUse with CautionDo not receive LUPROTAS 22.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs, or to any of the other ingredients of this medicine. KIDNEYUse with CautionLUPROTAS 22.5MG INJECTION should be used with caution in patients with renal impairment. Consult your doctor before receiving the medicine. LIVERUse with CautionLUPROTAS 22.5MG INJECTION should be used with caution in patients with hepatic impairment. Consult your doctor before receiving the medicine. HEART DISEASEMonitoring requiredLUPROTAS 22.5MG INJECTION should be used with caution in patients with congenital long QT syndrome and congestive heart failure only if clearly necessary. Consult your doctor before receiving. USE IN PEDIATRICSContraindicatedLUPROTAS 22.5MG INJECTION is not recommended for use in children. Consult your doctor before receiving. USE IN GERIATRICSUse with CautionLUPROTAS 22.5MG INJECTION should be used with caution in elderly patients (above 65 years). Consult your doctor before receiving the medicine. OTHERSBefore receiving LUPROTAS 22.5MG INJECTION, inform your doctor if you: have frequent electrolyte abnormalities have metastatic vertebral lesions have urinary tract obstruction have diabetes have a history of epilepsy have a history of cerebrovascular disorders have a history of central nervous system anomalies or tumours
Drug Interactions
SA. Drug-Drug Interactions: Before receiving LUPROTAS 22.5MG INJECTION, inform your doctor, if you are taking any of the following medicine: medicines that prolong the QT interval (Ex. haloperidol, amiodarone, erythromycin) Overdosage: LUPROTAS 22.5MG INJECTION will be given to you only by a doctor or nurse in a hospital, and so it is unlikely to receive an overdose. If you or anyone else accidentally receives too much of this medicine, consult your doctor immediately or visit the nearby hospital. Symptoms of overdose are shortness of breath, decreased activity, and increased scratching. SYNOPSIS Drug : Leuprolide Pharmacological Category : Gonadotropin Releasing Hormone (GnRH) Agonist Therapeutic Indication : Palliative management for advanced prostatic cancer Dosage Forms : Injection, Injection depot MORE INFORMATIONSTORAGE Keep LUPROTAS 22.5MG INJECTION out of reach of children Store between 2-8°C
Frequently Asked Questions
Common questions and answers about Luprotas 22.5mg Injection 1's.
What LUPROTAS 22.5MG INJECTION is used for?
LUPROTAS 22.5MG INJECTION for palliative management (relieving symptoms and minimize the associated suffering) of advanced prostatic cancer. Consult your doctor before receiving.
What side effects are seen with LUPROTAS 22.5MG INJECTION?
The most common side effects associated with the use of LUPROTAS 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in the upper respiratory tract, and fatigue. Consult your doctor if any of these symptoms worsens.
Who should avoid receiving LUPROTAS 22.5MG INJECTION?
Do not receive LUPROTAS 22.5MG INJECTION if you are allergic to leuprolide, GnRH, GnRH agonist analogs. It is not recommended for use in pregnant women, breastfeeding women, and children. Consult your doctor before receiving.
Is LUPROTAS 22.5MG INJECTION safe to use in children?
LUPROTAS 22.5MG INJECTION is not recommended for use in children because the safety and effectiveness of this medicine have not been established in this population. Consult your doctor before receiving.
Is LUPROTAS 22.5MG INJECTION safe to use in pregnant and breastfeeding women?
LUPROTAS 22.5MG INJECTION is not recommended for use during pregnancy as it may increase the risk for pregnancy loss. It is also not recommended for use in breastfeeding women as it can pass through milk. Consult your doctor before receiving.
What happens if you take more LUPROTAS 22.5MG INJECTION than your required dose?
LUPROTAS 22.5MG INJECTION will be given to you only by a doctor or nurse in a hospital, and so it is unlikely to receive an overdose. If you or anyone else accidentally receives too much of this medicine, consult your doctor immediately or visit the nearby hospital. Symptoms of overdose are shortness of breath, decreased activity, and increased scratching.
Is LUPROTAS 22.5MG INJECTION safe to use in heart patients?
LUPROTAS 22.5MG INJECTION should be used with caution in patients with congenital long QT syndrome and congestive heart failure only if clearly necessary. Consult your doctor before receiving.
Article Information
Written By
DETAILS Written By Dr. Janet.C
Medical Content Writer
Reviewed By
Dr. Sankara Babu Gorle
Medical Expert
Last Updated
22 Aug 2024